Mutational Profile Evaluates Response and Survival to First‐Line Chemotherapy in Lung Cancer
出版年份 2020 全文链接
标题
Mutational Profile Evaluates Response and Survival to First‐Line Chemotherapy in Lung Cancer
作者
关键词
-
出版物
Advanced Science
Volume -, Issue -, Pages 2003263
出版商
Wiley
发表日期
2020-12-30
DOI
10.1002/advs.202003263
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer
- (2019) Minjiang Chen et al. EBioMedicine
- Real-world outcomes of various regimens of recombinant human endostatin combined with chemotherapy in non-driver gene mutation advanced non-small cell lung cancer
- (2019) Zhongtai Wang et al. Cancer Medicine
- Genomic Signature of Driver Genes Identified by Target Next‐Generation Sequencing in Chinese Non‐Small Cell Lung Cancer
- (2019) Shiwang Wen et al. ONCOLOGIST
- Association between certain non–small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death‐ligand 1 inhibition
- (2019) Wenhua Liang et al. CANCER SCIENCE
- High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no driver alteration detected by DNA sequencing and low tumor mutation burden
- (2019) Ryma Benayed et al. CLINICAL CANCER RESEARCH
- Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non–Small Cell Lung Cancer Using a Clinicogenomic Database
- (2019) Gaurav Singal et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- What are the clinical symptoms and physical signs for non‐small cell lung cancer before diagnosis is made? A nation‐wide multicenter 10‐year retrospective study in China
- (2019) Pu‐Yuan Xing et al. Cancer Medicine
- Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade
- (2019) Steve Lu et al. JAMA Oncology
- NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018
- (2018) David S. Ettinger et al. Journal of the National Comprehensive Cancer Network
- Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors
- (2018) Neal I. Lindeman et al. Journal of Thoracic Oncology
- Overall survival of driver mutation-negative non-small cell lung cancer patients with COPD under chemotherapy compared to non-COPD non-small cell lung cancer patients
- (2018) Jeong Uk Lim et al. International Journal of Chronic Obstructive Pulmonary Disease
- Minimal functional driver gene heterogeneity among untreated metastases
- (2018) Johannes G. Reiter et al. SCIENCE
- NetSig: network-based discovery from cancer genomes
- (2017) Heiko Horn et al. NATURE METHODS
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- New and emerging targeted treatments in advanced non-small-cell lung cancer
- (2016) Fred R Hirsch et al. LANCET
- Targeted therapy for NSCLC with driver mutations
- (2013) Gabriele Minuti et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking
- (2010) Matthew D. Wilkerson et al. BIOINFORMATICS
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
- (2008) Giorgio Vittorio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started